Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from insulin therapy to saxagliptin + metformin in type 2 diabetes
2009-016745-25Phase 4Completed
- Sponsor
- IKFE
- Start
- Nov 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of saxagliptin, metformin, insulin glargine and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by IKFE. Primary endpoint: Stable HbA1c after switch. Started Nov 2009; status: completed.
02
Drugs
saxagliptinmetformininsulin glarginepioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016745-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016745-25.